Association between Resistin and High Sensitive Troponin I in St Elevation Myocardial Infarction and Systolic Heart Failure

Trisulo Wasyanto¹, Laurent Febrilia²

¹Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Sebelas Maret/ Dr. Moewardi Hospital, Surakarta
²Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Sebelas Maret

ABSTRACT

Background: Nearly half of all patients with acute myocardial infarction (AMI) have left ventricular systolic dysfunction and one-third have symptoms of heart failure (HF). In patients with AMI the resistin level correlated inversely with left ventricular ejection fraction (LVEF). Increased levels of high sensitive (hs) troponin I are associated with poorer prognosis. This study aimed to determine the association between levels of resistin and hs troponin I in ST elevation myocardial infarction (STEMI) patients with systolic HF.

Subjects and Method: This was a cross-sectional study was conducted at Dr. Moewardi General Hospital, Surakarta, from April 1 to May 31, 2018. A sample of 32 patients who admitted which diagnosed with STEMI was selected for this study. They were divided into two group according to result of LVEF measurement, LVEF < 40% and LVEF ≥ 40%. Blood examination and transthoracic echocardiography were performed to all patients. Correlation test using partial and multiple correlation test. To different 2 mean using Mann Whitney test.

Results: Mean of patient age was 59.5 years old. Resistin decreased LVEF (r= -0.41; p= 0.009), and it was statistically significant. Hs troponin I decreased LVEF (r= -0.25; p= 0.081), but it was marginally significant. Resistin level and hs troponin I increased LVEF (r= 0.47; p= 0.025), and it statistically significant.

Conclusion: There was an association between resistin and hs troponin I level together in STEMI patients with systolic HF. There was an association of resistin levels in STEMI patients with systolic HF. There was no association of hs troponin I levels in STEMI patients with systolic HF.

Keywords: Resistin, hs troponin I, STEMI, systolic heart failure.

Correspondence: Trisulo Wasyanto. Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Sebelas Maret/ Dr. Moewardi Hospital. Jl. Kol. Sutarto 132, Surakarta 57126, Central Java, Indonesia. Email: trisulo.wasyanto@gmail.com.
serum resistin levels correlate inversely with the left ventricular ejection fraction (LVEF), thus showing an increase in resistin related to the severity of injury ischemic myocardial (Chu et al., 2008). Other studies suggest that increased serum resistin in ST elevation myocardial infarction (STEMI) patients correlates with major adverse cardiac events (MACE) (Erer et al., 2014).

Resistin plays a role in the development of atherosclerosis as in studies on smooth muscle cell (SMC) and monocytes/macrophages. Resistin plasma levels have been shown to increase in inflammatory conditions. The expression of mRNA and resistin secretion is triggered by lipopolysaccharide (LPS) and TNF-α in leukocytes involved in the innate and adaptive immune system. At the same time resistin alone increases the inflammatory reaction by increasing pro-inflammatory cytokine production. Resistin together with other inflammatory cytokines can create changes that support the development of atherosclerosis (Kunnari, 2008). Serum resistin levels are associated with white blood count (WBC) and hsCRP. Resistin can also increase the activation of human endothelial cells by increasing the release of endothelin-1, adhesion cells and matrix metal proteinase which all causes proinflammatory activity and causes plaque instability. It can be said that resistin may play a role in the development of ACS by influencing plaque susceptibility through a series of pro-inflammatory cells and cytokines (Chu et al., 2008). A meta-analysis data reports that resistin levels correlate with cardiovascular death especially in high risk individuals (Fontana et al., 2015). Inflammatory markers such as interleukin (IL)-6, c reactive protein (CRP) and tumor necrosis factor-α(TNF-α) are independently correlated with cardiovascular events (Gencer et al., 2016). The direct effect of resistin to the expression of IL-1β, IL-6, IL-8 and TNF-α, compatible with multi cytokine resistance pathways associated with several risk factors for insulin resistance or low grade inflammation and MACE (Menzaghi et al., 2017). The direct mechanism of resistin to HF was demonstrated in neonatal mice with adenovirus-mediated over expression. In this study resistin resulted in increased sarcomere organization, cell size and protein synthesis in cardiomyocytes, as well as expression of atrial natriuretic factors and myosin heavy chains. The heart requires a high ATP to maintain mechanical function continuously, a decrease in ATP affects the myocardium which directly affects myocardial contraction and subsequently causes HF (Doenst et al., 2013).

High sensitivity troponin (hsTn) is recommended to be the standard of examination in the emergency department for patients with chest pain, replacing previous cardiac markers such as myoglobin, CKMB and troponin. This test is substantially more sensitive than the previous test but has low specificity for AMI, because it can detect myocardial injury from various causes (Morrow and Antman, 2009). Increased levels of hs Tn I are associated with a worse prognosis (Bonaca et al., 2010). In the event of an AMI, an increase in hsTn I level will occur, which is a unit that inhibits the troponin complex to associate with thin filaments, and inhibits the actin-myosin interaction of intracellular Ca2+, where changes in the Ca2+ role will also result in changes in regulation of myocardial contractility (Layland et al., 2005).

The purpose of this study was to determine the association between resistin levels and hs troponin I in ST elevation myocardial infarction (STEMI) patients with systolic HF.

SUBJECTS AND METHOD

1. Study Design
The study was conducted at the Emergency Room and Intensive Cardiovascular Care
Unit (ICVCU) at Dr. Moewardi General Hospital Surakarta in STEMI patients. This study uses a cross sectional design.

2. Population dan Sample
A total of 32 patients with STEMI who were treated at ICVCU of Dr. Moewardi General Hospital, from 1 April to 31 May 2018, was selected by consecutive sampling.

3. Study Variables
The dependent variable in this study was systolic Heart Failure. The independent variable in this study is resistin and high sensitive troponin I.

4. Study Instruments
The definition of STEMI patients is in accordance with the recommendations of the European Society of Cardiology (ESC) / American College of Cardiology Foundation (ACCF)/American Heart Association (AHA)/WHO task force (Thygesen et al., 2012). Exclusion Criteria: patients with acute aortic dissection, severe sepsis, malignancy, immunocompromised disorders and patients with chronic kidney disease. Systolic heart failure is defined as a left ventricular ejection fraction (LVEF) <40% by examination of the GE Vivid 6 brand echocardiography by Simpson’s method. Resistin levels were measured by the Elisa method by Prodia clinical laboratories. Hs troponin I levels were measured by Elisa's method by clinical laboratory of Dr. Moewardi hospital.

5. Data Analysis
Data analysis was performed using the Mann Whitney test.

6. Research Ethic
The research ethics include inside informed consent, identity confidentiality, and ethical clearance carried out in the Dr. Moewardi hospital, Surakarta.

RESULTS
The study subjects were 32 people with an average age of 59.5±9.59 years, divided into two groups, namely the group that had a LVEF of less than 40% by 15 people (46.9%) and the rest were the group that had the same LVEF or greater than 40% which was 17 people (53.1%).

The mean age of patients with LVEF <40% (58.47± 8.75) was not significantly different from patients with LVEF ≥40% (60.41 ±10.46) with p= 0.576. There were no significant differences in the onset of chest pain, urea, creatinine, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and HbA1c in patients with LVEF <40% and LVEF ≥ 40%.

The results of homogeneity testing of characteristic variables that are quantitative found that all of these characteristic variables are homogeneous. Testing the relationship of resistin and hs troponin I to the LVEF that shows systolic HF is done by correlation analysis, both partial correlation and a multiple correlation. Description and Test Results Homogeneity of quantitative variables of demographic and clinical characteristics in this study is in Table 3.

Resistin was negatively correlated with LVEF (r= -0.41; p= 0.009), and it was statistically significant. This means, if the resistin level is high, then there is a tendency for a significant decrease in LVEF and vice versa if the resistin is low then the LVEF will increase significantly. Hs troponin I was negatively correlated with LVEF (r= -0.25; p= 0.081), and it was marginally significant. This means, if the hs troponin I level is high or low there is no tendency to significantly increase or decrease LVEF. Resistin level and hs troponin I positively correlated with LVEF (r= 0.47; p= 0.025), and it was statistically significant. This means, if the levels of resistin and hs troponin I together are low or high then there will be a tendency for LVEF to increase or decrease significantly.

Table 3 showed the difference of 2 mean test of resistin and Hs troponin in LVEF <40% and LVEF ≥40%. Mean resistin
level in LVEF <40% (Mean= 27.81; SD= 16.99) was higher than LVEF ≥40% (Mean= 9.38; SD= 5.44), and it was statistically significant (p= 0.001). Hs Troponin I in LVEF <40% (Mean= 8833.25; SD= 9260.12) was higher than LVEF ≥40% (Mean= 4923.58; SD= 7601.43), but it was statistically non-significant (p= 0.0142). Table 3 showed the difference of 2 mean test of resistin and Hs troponin in LVEF <40% and LVEF ≥40%. Mean resistin level in LVEF <40% (Mean= 27.81; SD= 16.99) was higher than LVEF ≥40% (Mean= 9.38; SD= 5.44), and it was statistically significant (p= 0.001). Hs Troponin I in LVEF <40% (Mean= 8833.25; SD= 9260.12) was higher than LVEF ≥40% (Mean= 4923.58; SD= 7601.43), but it was statistically non-significant (p= 0.0142).

Table 1. Comparison of Variable Characteristics of Left Ventricular Ejection Faction Group <40% and Group ≥ 40%.

| Variable                  | LVEF< 40% | LVEF ≥ 40% | OR | p     |
|---------------------------|-----------|------------|----|-------|
| Gender                    |           |            |    |       |
| a. Male                   | 11        | 73.3       | 13 | 76.5  | 0.04 | 0.838 |
| b. Female                 | 4         | 20.7       | 4  | 23.4  |      |       |
| STEMl type                |           |            |    |       |
| a. Anteroseptal           | 2         | 13.3       | 2  | 11.8  |      |       |
| b. Anterior               | 2         | 13.3       | 5  | 29.4  |      |       |
| c. Anterior extensive     | 5         | 33.3       | 3  | 17.6  |      |       |
| d. Inferior               | 3         | 20.0       | 3  | 17.6  | 6.69 | 0.351 |
| e. Inferoposterior        | 1         | 6.7        | 1  | 5.9   |      |       |
| f. Inferior RV            | 0         | 0.0        | 3  | 17.6  |      |       |
| g. Inferoposterior RV     | 2         | 13.3       | 0  | 0     |      |       |
| Early Killip Class        |           |            |    |       |
| a. I                      | 8         | 53.3       | 12 | 70.6  |      |       |
| b. II                     | 6         | 40.0       | 4  | 23.5  | 1.08 | 0.583 |
| c. IV                     | 1         | 6.7        | 1  | 5.9   |      |       |
| DM                        |           |            |    |       |
| a. DM                     | 6         | 40.0       | 6  | 35.3  | 0.08 | 0.784 |
| b. Non DM                 | 9         | 60.0       | 11 | 64.7  |      |       |
| History of Hypertension   |           |            |    |       |
| a. Hypertension           | 10        | 66.7       | 6  | 35.3  | 3.14 | 0.077 |
| b. No hypertension        | 5         | 33.3       | 11 | 64.7  |      |       |
| Smoker status             |           |            |    |       |
| a. Smoker                 | 5         | 33.3       | 10 | 58.8  | 2.08 | 0.149 |
| b. Non smoker             | 10        | 66.7       | 7  | 41.2  |      |       |
| History of Dyslipidemia   |           |            |    |       |
| a. Yes                    | 5         | 33.3       | 4  | 23.5  | 0.38 | 0.538 |
| b. No Dyslipidemia        | 10        | 66.7       | 13 | 76.5  |      |       |
| Worsening Killip          |           |            |    |       |
| a. Yes                    | 3         | 20.0       | 2  | 11.8  | 0.41 | 0.522 |
| b. No                     | 9         | 80.0       | 15 | 88.2  |      |       |
| Death Event               |           |            |    |       |
| a. Yes                    | 4         | 26.7       | 2  | 11.8  | 1.16 | 0.281 |
| b. No                     | 11        | 73.3       | 15 | 88.2  |      |       |
| Arrhythmias               |           |            |    |       |
| a. Yes                    | 6         | 40.0       | 3  | 17.6  | 1.97 | 0.160 |
| b. No                     | 9         | 60.0       | 14 | 82.4  |      |       |
Table 2. Results of Correlation Analysis of Resistin and Hs Troponin I Variables with Left Ventricular Ejection Fraction

| Independent Variables       | r    | p    |
|-----------------------------|------|------|
| Resistin                    | -0.41| 0.009|
| Hs Troponin I               | -0.25| 0.081|
| Resistin and Hs Troponin I  | 0.47 | 0.025|

Table 3. Difference 2 Mean Test of Resistin and Hs Troponin Variable in LVEF <40% and LVEF ≥ 40%

| Variable         | LVEF <40% (n=15) | LVEF ≥ 40% (n= 17) | p    |
|------------------|-------------------|---------------------|------|
|                  | Mean   | SD     | Mean   | SD     |      |
| Resistin         | 27.81  | 16.99  | 9.38   | 5.44   | 0.001|
| Hs Troponin I    | 8833.25| 9260.12| 4923.58| 7601.43| 0.142|

Table 4. Results of Correlation Analysis of Sample Characteristics on Resistin and Hs Troponin I

| Independent Variables         | Resistin | p    | Hs Troponin I | p    |
|-------------------------------|----------|------|---------------|------|
| Gender                        | 0.01     | 0.991| -0.24         | 0.810|
| Smoker status                 | 1.89     | 0.068| 0.38          | 0.708|
| History of hypertension       | 1.68     | 0.104| 0.07          | 0.945|
| DM                            | -1.05    | 0.303| 0.92          | 0.385|
| Azotemia                      | 1.52     | 0.139| 0.88          | 0.385|
| Dyslipidemia                  | 0.47     | 0.646| 1.49          | 0.147|
| Early Killip Class            | 0.17     | 0.848| 6.15          | 0.006|
| STEMI type                    | 2.79     | 0.032| 0.78          | 0.594|
| Arrhythmia Events             | 0.80     | 0.433| -0.20         | 0.844|
| Death Events                  | 3.35     | 0.002| 1.24          | 0.225|
| Worse Class Killip            | 1.36     | 0.186| -0.14         | 0.890|

Figure 1. ROC Analysis of Resistin for Systolic Heart Failure

- AUC: 0.91
- Sensitivity: 86.7%
- Specificity: 82.4%
The ROC curve generated from the resistin variable for the identification of systolic HF resulted in an Area under Curve (AUC) value of 0.914 or included in the excellent category. It can be interpreted that the resistin variable identifies very well the incidence of systolic HF based on the LVEF variable benchmarks. Based on the ROC curve, the Cut of Point value of the resistin variable is 11.74 ng/mL with a cut of point of the resistin variable of 11.74 ng/mL, the systolic heart failure event can be identified from the resistin variable having a sensitivity level of 86.7% with a specificity level of 82.4% and an accuracy rate of 84.4%.

Meanwhile the ROC curve generated from the hs troponin I variable for identification of systolic HF resulted in an Area under Curve (AUC) value of 0.66 or included in the weak category. It can be interpreted that hs troponin I variable is weak in identifying systolic HF based on the LVEF variable benchmark. Based on the ROC curve, the Cut of Point value of the Hs troponin I variable is 5,124.50 ng/L. With the cut of point of the Hs troponin I variable of 5,124.50 ng/L, the systolic heart failure can be identified from the Hs troponin I variable has a sensitivity level of 60.0% with a specificity level of 76.5% and an accuracy rate of 68.7%.

Figure 2. ROC Analysis of Troponin I against Systolic Heart Failure

DISCUSSION

In this study, HF patients were divided into two groups, namely HF patients with LVEF <40% categorized as systolic HF and HF patients with LVEF ≥40%. In a large sample study, the Immediate Myocardial Metabolic Enhancement during Initial Assessment and Treatment in Emergency care (IMMEDIATE) Trial in 2016, stated that there were significant differences in post ACS patients with LVEF <40% and had a 1-year mortality rate or HF hospitalization higher than patients with LVEF>40% (Mukherjee et al., 2016). The results of this study indicate that the level of resistin and LVEF has a significant negative correlation at a significance level of 5% (p <0.05) with a correlation value of $r = -0.414$. This means, if the level of resistin increases then
there is a tendency for a significant decrease in LVEF and vice versa if the value of resistin is low then the LVEF will experience a significant increase. There was a significant difference in resistin levels in LVEF <40% with LVEF ≥40% with p <0.001. The results of this study are consistent with previous studies that serum resistin levels are inversely correlated with LVEF, so that an increase in resistin levels correlates with the severity of myocardial ischemic in ACS patients (Chu et al., 2008).

Hs troponin I decreased LVEF, but it was statistically non-significant (r= -0.25; p>0.05). In addition, there was no difference between Hs troponin I levels in LVEF <40% or with LVEF ≥ 40% with p= 0.142. The possibility of this result could be due to Troponin I level had a peak time of around 12 hours and subsequently decreased, whereas patients who come to the emergency room have different onset of STEMI event (Maha-jan and Jarolim, 2011).

Combination of resistin and Hs troponin I increased LVEF and it was statistically significant (r= 0.47; p <0.05).

By using the ROC curve method, it was found that the level of resistin for the identification of systolic HF resulted in an Area under Curve (AUC) value of 0.914 or included in the excellent category. Based on the ROC curve, the cut of point value is 11.74 ng/mL. With the cut of point level of resistin of 11.74 ng/mL, the incidence of systolic HF can be identified from the resistin level which has a sensitivity level of 86.7% and a specificity level of 82.4%, and an accuracy rate of 84.4%; better when compared to Hs troponin I level which has a sensitivity level of 60% and specificity of 76.5%, and an accuracy rate of only 68.7%. The results of this study indicate that if there are 100 STEMI patients with resistin levels >11.74 ng/mL, 91 of them are predicted to experience systolic HF.

In this study, resistin levels were related to the extent of infarction in STEMI patients. These results are consistent with research conducted by Zhang et al., that increased serum resistin levels are related to the severity of coronary heart disease (Zhang et al, 2017). The results of this study also showed that resistin levels were associated with death in STEMI patients (p= 0.002). This is also consistent with the results of other researchers, that resistin levels is correlated with MACE events where one of them is cardiovascular death (Menzagli et al., 2017; Fontana et al., 2015; Erer et al., 2014).

Based on the results of this study, it can conclude that there is a correlation between resistin and hs troponin I level in STEMI patients with systolic HF. There is a correlation between resistin levels in STEMI sufferers with systolic HF. Resistin levels have a prognostic value for the occurrence of systolic HF in STEMI patients with better sensitivity, specificity, and accuracy than hs troponin I levels.

**AUTHOR CONTRIBUTION**

Trisulo Wasyanto and Laurent Febrilia collected the data, measured resistin level, examined clinical changes, did data analysis, and wrote the manuscript.

**CONFLICT OF INTEREST**

The authors declare there is no conflict of interest.

**FUNDING AND SPONSORSHIP**

No external funding and sponsorship.

**ACKNOWLEDGEMENT**

We would like to thank to Dr. Moewardi Hospital that give permission to collect the data.
REFERENCE

Bonaca M, Scirica B, Sabatine M, Dalby A, Spinar J, Murphy SA, et al (2010). Pro-spective evaluation of the prog-nostic implications of improved assay perfor-mance with a sensitive assay for cardiac Troponin I. J Am Coll Cardiol. 55: 21-18-25. doi: 10.1016/j.jacc.2010.01.0-4-4.

Chu S, Ding W, Li K, Pang Y, Tang C (2008). Plasma resistin associated with myo-cardium injury in patients with acute coronary syndrome. Circ J. 72: 1249–53.

Doenst T, Nguyen TD, Abel ED (2013). Cardiac Metabolism in Heart Failure-Implications beyond ATP production. Circulation. 113(6): 709–24. doi: 10.-11-61/CIRCRESAHA.113.300376.

Erer HB, Sayar N, Guvenc TS, Aksaray S, Yilmaz H, Altay S, Turer A, Oz TK, et al. (2014). Prognostic Value of Serum Resistin Levels in Patients with Acute Myocardial Infarction. Kardiol Pol. 72-(2): 181–6. doi: 10.5603/K-P.a2013.-0086.

Fontana A, Spadaro S, Copetti M, Spoto B, Salvemini L, Pizzini P, et al. (2015). Association between resistin levels and all cause and cardiovascular mortality: A new study and a system-atic review and meta-analysis. Plos One. 10(3): E0120419. doi: 10.1371/journal.pone.-01-20419.

Gencer B, Auer R, Rekeneire N, et al. (2016). Association between resistin levels and cardiovascular disease events in older adults: the health, aging and body composition study. J Atherosclerosis. (245): 181-186. doi:10.1016/j.atherosclerosis.2015-.12.004.

Kunnari A (2008). Genetic, Epidemiologi-cal and Cell Culture Studies on Hu-man Resistin. http://herkules.o-ulu.-fi/is-bn-9789514289477/.

Layland J, Solaro RJ, Shah AM (2005). Regulation of cardiac contractile func-tion by troponin I phosphorylation. Cardiovasc Res. 66(1): 12-21. Doi: https://doi.org/10.1016/j.cardiores.-2004.12.022.

Mahajan VS, Jarolim P (2011). How to Interpret elevated cardiac troponin lev-els. Circulation, 124(21): 2350-4. https://doi.org/10.1161/CIRCULATIONAHA.111.023697.

Menzaghi C, Marucci A, Antonucci A, De Bonis C, Moreno LO, Salvemini L, et al. (2017). Suggestive evidence of a multi-cytokine resistin pathway in humans and its role on cardiovascular events in high-risk individuals. Nature. 7: 44337. Doi: 10.10-38/srep44337.

Morrow DA, Antman EM (2009). Eval-uation of high-sensitivity assays for cardiac troponin. Clin Chem. 55(1): 5-8. doi: 10.1373/clinchem.2008.117218

Mukherjee JT, Beshansky JR, Ruthazer R, Alkofide H, Ray M, Kent D, Manning WJ, Huggins GS, Selker HP (2016). In hospital measurement of left ventricular ejection fraction and one year outcomes in acute coronary syndromes: Results from The IMMEDIATE Trial. Cardiovasc Ultrasound. 14(1): 29. doi: 10.1186/s12947-016-0068-1.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gon-zález-Juanatey JR, et al. (2016). 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 37(27): 2129-
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD (2012). Third universal definition of myocardial infarction. J Am Coll Cardiol. 60: 1581-9. https://doi.org/10.1161/CIR.0b013e31826e1058.

Zhang YX, Li YX, Yu L, Zhou L (2017). Association between serum resistin concentration and hypertension: A systematic review and meta-analysis. Oncotarget. 8(25): 41529-37. doi: 10.18632/oncotarget.17561